Hagens Berman再次提示Capricor证券集体诉讼与Q2电话会未设Q&A

SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following Capricor's recent Q2 2026 earnings release and conference call—notable for an omission of management Q&A with analysts—the company is facing uncertainty amid an active securities fraud class action.
Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now. The court-appointed lead plaintiff deadline in the class action is September 28, 2026.
Capricor Q2 2026 Earnings: Omission of Q&A
Capricor's recent Q2 2026 financial report and investor conference neglected to address investor concerns regarding its ongoing legal and regulatory pressures. Management reported a net loss of $40.7 million, alongside $237.9 million in cash and marketable securities. Uniquely, Capricor did not hold a live question-and-answer session with analysts at the end of the earnings call. Management cited the sensitivity of ongoing, real-time discussions with the FDA regarding their regulatory path as the reason for skipping analyst Q&A, and thus management did not address questions about the trial data integrity or legal fallout.
Securities Class Action Details & Overview
- Class Period: Dec. 17, 2025 – July 26, 2026
- Lead Plaintiff Deadline: Sept. 28, 2026
- Visit: www.hbsslaw.com/cases/capricor-therapeutics-inc-capr-securities-class-action
Core Allegations and Background
- Material Misleading Statements Regarding Clinical Trial Data and SAP Changes: The lawsuit alleges that Capricor and certain executives made materially false and misleading statements regarding the clinical trial data and regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).
- The HOPE-3 Trial Breakthrough and Subsequent Capital Raise: On December 3, 2025 Capricor announced "Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy." The company's CEO said "HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function." Driven by these claims, Capricor's share price surged 370% to close up $23.60 on December 3, 2025. The following day, the company launched a public stock offering of approximately 6 million shares priced at $25 per share.
- FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse: Capricor's public assurances unraveled on July 27, 2026, when the FDA published briefing documents ahead of an Advisory Committee meeting. The documents revealed that Capricor made unagreed-upon post-hoc modifications to its pre-specified Statistical Analysis Plan (SAP). The FDA stated that the HOPE-3 study "did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months". Capricor shares crashed roughly 64% in a single day to close at $7.00. An Advisory Committee subsequently voted 9–3 against the efficacy of the drug, compounding investor losses.
Hagens Berman's Investigation
"We're focused on investors' losses and uncovering the full scope of how management characterized these trial endpoints and undisclosed modification," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation on the claims alleged in the pending suit.
What Affected CAPR Investors Should Do
If you purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026, and suffered significant financial losses, you have until September 28, 2026, to ask the court to appoint you as lead plaintiff. You do not need to seek lead plaintiff status to share in any potential recovery.
To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/cases/capricor-therapeutics-inc-capr-securities-class-action.
If you'd like more information and answers to frequently asked questions about the Capricor case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP